Recursion Pharmaceuticals Inc (RXRX) Options

balding haircut at RXRX

RXRX, under $7

out for now, let CEO work his magic if he has one under his sleeve

is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.

RXRX

RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......

RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.

market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.

RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.

Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%

Rxrx share price Long Tail Up since 06 Dec 2024.

Phase 1 news expected tonight at conference.

Phase 1 news expected tonight at conference.

this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...

Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!

Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.

RxRx going to be top player in future pharma drug discovery

Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.

GOOG -- RxRx -- NVDA -- RxRx -- MSFT

agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year

no it is the PLTR of Drug discovery
both rely on NVDA to run fast

started buying little little- this is NVDA of DRUG DISCOVERY

$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.

high potential if delivers,

Good gains in past week, but looks like it is getting ready to drift lower again.

First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study

Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX

$RXRX - Having a huge day here!!

$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo

Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.

RXRX 10Q 11/6

RXRX under $10

RXRX under $10

https://x.com/RecursionPharma/status/1841453309342740925

So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline

WALL @ $7.5 , $7.0

https://www.stockscores.com/charts/charts/?ticker=RXRX

Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX

diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT

RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT

Yes, I've been adding shares of RXRX this week.

LC

RXRX

Looks.like a little dilution, but a good buying opportunity, to add some more.

Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX

I had not seen that merger announcement. Never came across in my broker news feed.

Did you see the possible merger news?

LC

RXRX

Running millions of tests per week, to find promising drug candidates.

What we do not know, is how many candidates have entered clinical trials.

When news pops about RXRX origination of promising cures, this will skyrocket.

Oops, missed this one:

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease

Looks ready to move IMO.

LC

RXRX

Looking for a move into the 9.25-9.50 range within the next few weeks.

RXRX looks ready for another move upward.